blockbuster drugs
TRANSCRIPT
-
8/3/2019 Blockbuster Drugs
1/18
BLOCKBUSTER DRUGS
END OF THE ERA?
YET NEW AVENUES..
1MBA(pharma tech) IVth YEAR
KAKULI SINHA
ROLL -18
DIV- A
-
8/3/2019 Blockbuster Drugs
2/18
2MBA(pharma tech) IVth YEAR
-
8/3/2019 Blockbuster Drugs
3/18
1. END OF BLOCKBUSTERERA.
2. DRY R&D PIPELINE
3. DRUG PRICING PRESSURES
4. STRICT REGULATORY
REQUIREMENTS
PHARMACEUTICAL
INDUSTRY :
DRAMATIC CHANGE
3MBA(pharma tech) IVth YEAR
-
8/3/2019 Blockbuster Drugs
4/18
4MBA(pharma tech) IVth YEAR
THE DRY DESERT OF PATENT EXPIRATION
-
8/3/2019 Blockbuster Drugs
5/18
5MBA(pharma tech) IVth YEAR
-
8/3/2019 Blockbuster Drugs
6/18
6MBA(pharma tech) IVth YEAR
-
8/3/2019 Blockbuster Drugs
7/18
MBA(pharma tech) IVth YEAR 7
Fig: This figure demonstrates the sharp fall(26.78%) in the stock price of Merck, on
September 30, 2004 .
Source: 12 PR catastrophe that crushed company shareholders, Alyson shontell,
Oct 30,2010
-
8/3/2019 Blockbuster Drugs
8/18
WHAT NEXT???
SHIFT FROM MARKET SHARE CAPTURE TO MARKET
CREATION.
ADOPT DIFFERENTIATED STRATEGIES AND BUSINESS
MODEL.
8MBA(pharma tech) IVth YEAR
-
8/3/2019 Blockbuster Drugs
9/18
ENSURING ACCESSIBILITY.
STRENGTHEN SALES AND MARKETING
CAPABILITIES.
9MBA(pharma tech) IVth YEAR
-
8/3/2019 Blockbuster Drugs
10/18
INNOVATION AND NEW TECHNOLOGIES
UNTAPPED POTENTIAL OF BIOTECHNOLOGY Excellent alternative to dried pipelines
improved safety profiles, efficacies and cost to
benefit ratio The biologics sector is experiencing robust
growth. The rate of sale of biotech products is
double that of pharmaceuticals in the last year
10MBA(pharma tech) IVth YEAR
-
8/3/2019 Blockbuster Drugs
11/18
Biologics are almost impossible to replicate becauseeach one of it is uniquely dependent on the cell line
and the manufacturing process used.
There is no regulatory norm through which FDA can
grant biosimilars or follow-on biologics approval
11MBA(pharma tech) IVth YEAR
-
8/3/2019 Blockbuster Drugs
12/18
PHARMACOGENOMICS AND PERSONALISED
MEDICINE
right drug for the right patient.
It describes how an individuals genetic
inheritance affects bodys response to drugs.
12MBA(pharma tech) IVth YEAR
-
8/3/2019 Blockbuster Drugs
13/18
GENE VARIANTS IDENTIFIED
BIOMARKERS- STRATIFICATION INTO SUBGROUPS.
BEST TREATMENT FOR EACH SUBGROUP
13MBA(pharma tech) IVth YEAR
-
8/3/2019 Blockbuster Drugs
14/18
CANCER: SETTING THE BEST EXAMPLE
14MBA(pharma tech) IVth YEAR
-
8/3/2019 Blockbuster Drugs
15/18
15MBA(pharma tech) IVth YEAR
-
8/3/2019 Blockbuster Drugs
16/18
CONCLUSION
Pharmaceutical firms must refocus its energy to
discover superior drugs that will genuinely help
sick people.
. Biotech and personalized drugs offer an ideal
platform to do this.
16MBA(pharma tech) IVth YEAR
-
8/3/2019 Blockbuster Drugs
17/18
Two developments will help the industry reinvigorate its
pipeline:
First, the widespread recognition of the fact that the
commercial potential of drugs that fit the conventional
therapeutic product profile is declining.
Second, the increase in the understanding and application
of the molecular sciences.
17MBA(pharma tech) IVth YEAR
-
8/3/2019 Blockbuster Drugs
18/18
18MBA(pharma tech) IVth YEAR